A spectroscopy measurement device according to the present embodiment comprises: a lamp light source (160) for generating lamp light having a plurality of emission lines; a plurality of inorganic materials; an objective lens (50) on which the lamp light and Raman scattered light from the plurality of inorganic materials impinge; a spectrometer (60) that spectrally detects the lamp light and the Raman scattered light from the objective lens (50); and a processing unit (70) that calculates a calibration wavelength axis of the spectrometer (60) on the basis of the wavelengths of the plurality of emission lines, calculates the incident wavelength of the laser light on the basis of the Raman bands of the Raman scattered light on the calibration wavelength axis, and converts the calibration wavelength axis to a wavenumber axis using the incident wavelength.
The present invention accurately evaluates the effects, on organs at risk, of radiation from radiation sources. This radiation dose analysis method comprises a reference axis determination step (S1) for: acquiring a three-dimensional medical image, which is an image obtained by imaging a subject present where an applicator (50) capable of accommodating a radiation source is installed in the vicinity of an object to be irradiated with radiation emitted from the radiation source, said image showing the installed applicator; and determining a reference axis of the applicator (50) shown in the three-dimensional medical image. Said method also comprises a first radiation dose analysis step (S4) for analyzing, on the basis of a distance from the reference axis of each of a plurality of virtual cylindrical surfaces having different radii with the reference axis serving as the central axis, a radiation dose reaching each of the plurality of virtual cylindrical surfaces from the radiation source.
The present invention provides an image classification learning device that makes it possible to learn a "concept" to be used by a post-learning model to make a determination. A concept learner 200 performs machine learning of a plurality of concepts in image data on the basis of learning data including the image data and an image label. A concept prototype processing unit 2100 is an attention mechanism that, in a concept matrix comprising slot vectors, converts the slot vectors according to image features defined in the slot vectors, the slot vectors respectively corresponding to a plurality of concepts and defining an image region in which feature quantities emphasized in identification processing by an image identification means appear. A learning processing control unit 700 controls learning processing so as to decrease a loss calculated on the basis of: an identification loss that decreases as the identification rate of a classifier 400 increases, and a separation loss that decreases as the degree of mutual separation of the feature quantities corresponding to the plurality of concepts in a feature quantity space increases.
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
G06V 10/77 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
[Problem] To directly bond a metal layer in the shape of a thin line to a surface of a ceramic substrate. [Solution] A method for producing a ceramic/metal bonded object which comprises: causing laser beams to strike on a surface of a ceramic substrate while sweeping the laser beams; simultaneously therewith, feeding a solid metallic material toward a region (hereinafter, referred to as "irradiated area") in the ceramic-substrate surface, the region being irradiated with the laser beams, so that the metallic material being supplied is also in the state of being irradiated with the laser beams, thereby melting the metallic material while heating the ceramic-substrate surface located in the irradiated area; and causing the molten metallic material to adhere to the ceramic-substrate surface and then solidifying the metallic material.
C23C 24/10 - Revêtement à partir de poudres inorganiques en utilisant la chaleur ou une pression et la chaleur avec formation d'une phase liquide intermédiaire dans la couche
C23C 26/00 - Revêtements non prévus par les groupes
C23C 26/02 - Revêtements non prévus par les groupes par application au substrat de matériaux fondus
5.
METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ICM (INSTITUT DU CERVEAU ET DE LA MOELLE EPINIÈRE) (France)
SORBONNE UNIVERSITÉ (France)
OSAKA UNIVERSITY (Japon)
Inventeur(s)
Cartier-Lacave, Nathalie
Besnard-Guerin, Corinne
Rousselot, Lisa
Mochizuki, Hideki
Tada, Satoru
Abrégé
The present invention relates to the treatment alpha-synucleinopathies. In this study, the inventors showed that restoring brain cholesterol pathway and defective autophagy by AAV- CYP46A1 delivery, as evidenced in several neurodegenerative pathologies, could be a relevant therapeutic approach in alpha-synucleinopathies and particularly in PD. Thus the present invention relates to a vector for use in the treatment of alpha-synucleinopathies, which vector comprises the full sequence of cholesterol 24-hydroxylase encoding nucleic acid.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
In the present invention, each of a plurality of pieces of training data used for creating a learned model for estimating a plan of a subject includes information on brain waves and is used for machine learning on the basis of at least some of a plurality of parameters. The program causes a computer to execute a step for creating a plurality of learned models by performing machine learning on each of a plurality of sets of a plurality of parameters, a step for calculating sensitivity and specificity with respect to each of the plurality of learned models, and a step for displaying a plurality of mosaic graphs on the same screen. Each of the plurality of mosaic graphs indicates information on the sensitivity in at least some of the plurality of sets. Assumed specificities with respect to the plurality of mosaic graphs are different from one another.
A glass powder composite comprising: a first glass powder which contains a first glass containing at least one type of element and from which the first glass elutes in a first period; and a second glass powder which contains a second glass containing at least one element different from the element of the first glass, and from which the second glass elutes in a second period different from the first period.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
Inventeur(s)
Tsutsui Makusu
Kawai Tomoji
Yokota Kazumichi
Abrégé
Provided are an ionic current measurement method and an ionic current measurement device capable of increasing an S/N ratio of a measurement result of a change in an ionic current. The ionic current measurement device comprises a board having a first surface and a second surface, a through-hole that penetrates through from the first surface toward the second surface to allow a charged sample to pass through, a first chamber member which, together with a surface of the first surface including a first opening of the through hole forms a first chamber that is filled with a first electrolytic solution, and a second chamber member which, together with a surface of the second surface including a second opening of the through hole forms a second chamber that is filled with a second electrolytic solution, and the ionic current measurement method includes a step for applying a voltage across the first electrolytic solution and the second electrolytic solution to cause the charged sample contained in one of the chambers to pass through the through-hole in a direction toward the other chamber, and a step for measuring a change in an ionic current when the charged sample passes through the through-hole. Furthermore, the first electrolytic solution and the second electrolytic solution have different dielectric constants.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present invention addresses the problem of providing a cMLCK activator which can enhance myocardial contraction without the need to increase the concentration of calcium in cells. The problem is solved by a cMLCK activator comprising a 8-hydroxyquinoline compound represented by general formula (I) (wherein R1represents a hydrogen atom or the like; R2represents R7CO- (wherein R71-61-6 alkyl group or the like) or the like; R3represents a hydrogen atom or the like; and R4, R5and R6 each independently represent a hydrogen atom or the like) or a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt.
C07D 215/28 - Alcools; Leurs éthers avec les atomes d'halogènes ou les radicaux nitro en positions 5, 6 ou 7
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 455/04 - Composés hétérocycliques contenant des systèmes cycliques quinolizine, p.ex. alcaloïdes de l'émétine, protoberbérine; Dérivés alkylènedioxy des dibenzo [a, g] quinolizines, p.ex. berbérine contenant des systèmes cycliques quinolizine directement condensés avec au moins un carbocycle à six chaînons, p.ex. protoberbérine; Dérivés alkylènedioxy des dibenzo [a, g] quinolizines, p.ex. berbérine contenant un système cyclique quinolizine condensé avec un seul carbocycle à six chaînons, p.ex. julolidine
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppression action. Also provided are induced regulatory T cells containing a chimeric antigen receptor (CAR). The present disclosure provides the pharmaceutical composition for treating or preventing T cell-related disorders, the composition containing, as an active ingredient, induced regulatory T cells having at least one characteristic selected from the group consisting of CTLA4 positivity, NT5E positivity, ITGAE (CD103) positivity, and AREG positivity. The present disclosure provides induced regulatory T cells containing a chimeric antigen receptor (CAR).
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p.ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 5/14 - Médicaments pour le traitement des troubles du système endocrinien des hormones thyroïdiennes, p.ex. T3, T4
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Provided are an exceptional agent and method for inducing differentiation from dental pulp cells into odontoblasts. Also provided are an exceptional pharmaceutical composition and pulp capping agent for dentin regeneration. This agent for inducing differentiation from dental pulp cells into odontoblasts contains an ammonium salt and at least one selected from the group consisting of halous acids, halous acid ions, and halites. Furthermore, the pharmaceutical composition and/or pulp capping agent for dentin regeneration has the aforementioned differentiation-inducing agent as an active ingredient. More specifically, the differentiation-inducing agent induces differentiation from dental pulp cells into odontoblasts by causing desulfation of the sulfate groups of heparan sulfate proteoglycans on the dental pulp cell surface.
Provided are: an orthogonal modulation device that is capable of measuring, with excellent precision, the spuriousness of modulated waves without limiting the performance of a circuit configuration; a method for measuring spuriousness; and a method for correcting orthogonal modulation. This orthogonal modulation device 12 has a modulation unit 17 and a measurement unit 18, the modulation unit 17 having a first orthogonal modulation unit 21 that outputs an orthogonally modulated TX1 signal, and a second orthogonal modulation unit 22 that outputs an orthogonally modulated TX2 signal. The TX1 signal and the TX2 signal include desired waves having the same frequency as each other. When local leaks and image components of the TX1 signal and the TX2 signal are measured by the measurement unit 18, the desired waves of the TX1 signal and the desired waves of the TX2 signal are adjusted so as to be inverted at the same amplitude as each other, and the local leaks and image components are measured from synthesized waves of the TX1 signal and the TX2 signal.
NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (Japon)
OSAKA UNIVERSITY (Japon)
Inventeur(s)
Yokota Takanori
Yoshioka Kotaro
Kuroda Takayuki
Obika Satoshi
Yamaguchi Takao
Abrégé
The present invention addresses the problem of providing a novel nucleic acid molecule capable of simultaneously achieving both a high gene regulatory effect and toxicity reduction. Provided is a nucleic acid molecule that contains a base sequence that is complementary to at least a portion of a target gene or a transcription product thereof and that has an antisense effect on the target gene or a transcription product thereof, the nucleic acid molecule: containing [1] a center region containing at least three continuous deoxyribonucleosides, [2] a 5' wing region that is disposed on a 5'-end side of the center region and that contains a nonnatural nucleoside, and [3] a 3' wing region that is disposed on a 3'-end side of the center region and that contains a nonnatural nucleoside; and containing a 5'-modified nucleoside represented by formula (I) at the first, third, and/or ninth base positions from the 5' side of the center region.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c. à d. autres que le ribose ou le 2'-désoxyribose
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
14.
RADIOLABELED TYROSINE DERIVATIVE AND APPLICATION THEREOF
The prevent invention provides a radiolabeled tyrosine derivative which has excellent LAT1 selectability, higher retention at a tumor or cancer site, and a degree of clearance that does not cause side effects, and which can be safely manufactured at favorable purity by a safe method suitable for industrial production. The present invention provides a radiolabeled compound represented by formula (I), or a pharmaceutically-acceptable salt thereof. [In the formula, each symbol is as defined in the description.]
C07C 229/34 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Niioka, Hirohiko
Sato, Junya
Takamatsu, Tetsuro
Matsumoto, Tatsuya
Nakao, Ryuta
Tanaka, Hiroyuki
Maebara, Syoji
Fukai, Shigeyuki
Abrégé
The present invention achieves an image translation device, for example, that can effectively utilize an existing diagnostic imaging model. An image translation device (1) comprises an image translation unit (22) that includes a first generator (221) and a second generator (222), the image translation unit (22) having learned the relationship between a color-related feature of a first image group obtained by capturing images of a tissue on which a first process including an embedding process and slicing has been performed, and a color-related feature of a second image group obtained by capturing images of the tissue on which a second process that does not include the embedding process and slicing has been performed. A first object image belonging to the first image group or a second object image belonging to the second image group is input to the image translation unit (22), which then outputs a first translation image generated from the first object image or a second translation image generated from the second object image.
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
16.
CHEMICAL REACTION METHOD, REACTION VESSEL, AND REACTION DEVICE
Provided are a method for efficiently carrying out a chemical reaction, and a reaction vessel. The method comprises inserting, into a reaction vessel, a mixed solution containing a polar solute and a non-polar solute, separating the mixed solution in the reaction vessel into a first solution layer containing primarily the polar solute and a second solution layer containing primarily the non-polar solute, allowing light outside the reaction vessel to transmit primarily through the layer with lower light absorption among the first solution layer and the second solution layer, irradiating the light thereof toward the interface between the first solution layer and the second solution layer, and chemically reacting the polar solute and the non-polar solute. The reaction vessel is for the insertion of a mixed solution of a polar solute and a non-polar solute, and is provided with a light-guiding unit that is arranged such that light outside the reaction vessel is incident inside the reaction vessel and is transmitted primarily through the layer with lower light absorption among the first solution layer containing primarily the polar solute and the second solution layer containing primarily the non-polar solute, and the light is irradiated towards the interface between the first solution layer and the second solution layer.
C07C 51/29 - Préparation d'acides carboxyliques, de leurs sels, halogénures ou anhydrides par oxydation avec des composés contenant des atomes d'halogène, ceux-ci pouvant être formés in situ
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaire; Appareils à cet usage utilisant des radiations électromagnétiques
B01J 19/18 - Réacteurs fixes avec éléments internes mobiles
B01F 23/43 - Mélange, p.ex. dispersion ou émulsion, selon les phases à mélanger Émulsion en utilisant des agitateurs entraînés
B01F 27/808 - Mélangeurs à agitateurs tournant dans des récipients fixes; Pétrins avec des agitateurs tournant autour d'un axe sensiblement vertical avec des agitateurs entraînés par le fond du récipient
B01F 33/40 - Mélangeurs utilisant l'agitation de gaz ou de liquide, p.ex. avec des tubes d'alimentation en air
B01F 33/45 - Mélangeurs magnétiques; Mélangeurs avec agitateurs à entraînement magnétique
B01F 33/452 - Mélangeurs magnétiques; Mélangeurs avec agitateurs à entraînement magnétique en utilisant des éléments d'agitation flottants indépendants
17.
POLYMER, RESIST COMPOSITION CONTAINING SAID POLYMER, METHOD FOR MANUFACTURING MEMBER USING SAME, AND PATTERN FORMATION METHOD
Provided are: a polymer which mitigates sensitivity decrease caused by a decrease in energy application density in patterning performed by irradiation with strong particle beams or electromagnetic waves of particles and photon energy and which is used in a resist composition having excellent development contrast characteristics and etching resistance; a resist composition containing said polymer; a method for manufacturing a member using said resist composition; and a pattern formation method. The polymer includes: a unit A which has an onium salt structure and generates acid by irradiation with particle beams or electromagnetic waves; and an organometallic compound-containing unit B having a metal atom selected from the group consisting of Sn, Sb, Ge, Bi, and Te, wherein the unit A is a polymer represented by formula (1). (In general formula (1), R1is one selected from the group consisting of a hydrogen atom, a linear, branched, or cyclic C1–C6 alkyl group, and a linear, branched, or cyclic C2–C6 alkenyl group, and at least one hydrogen atom in the alkyl group and alkenyl group in R1may be substituted with a substituent; L is one selected from the group consisting of a direct bond, a carbonyl oxy group, a carbonyl amino group, a phenylene diyl group, a naphthalene diyl group, a phenylene diyl oxy group, a naphthalene diyl oxy group, a phenylene diyl carbonyl oxy group, a naphthalene diyl carbonyl oxy group, a phenylene diyl oxy carbonyl group, and a naphthalene diyl oxy carbonyl group; Sp is one among a direct bond, a linear, branched, or cyclic C1–C6 alkylene group which may have a substituent, and a linear, branched, or cyclic C2–C6 alkenylene group which may have a substituent, and at least one methylene group in Sp may be substituted with a divalent heteroatom-containing group; M+is a sulfonium cation group or an iodonium cation group; X-is a monovalent anion group; f is an integer of 2-4, and f X-bonded to R, f M+corresponding to X-, f R1, f L, and f Sp may be respectively the same as or different from each other; and R is a C1-C6 f-valent hydrocarbon group which may have a substituent, at least one hydrogen atom in R may be substituted with a substituent, and at least one methylene group in R may be substituted with a divalent heteroatom-containing group.)
C08F 8/00 - Modification chimique par post-traitement
C08F 212/14 - Monomères contenant un seul radical aliphatique non saturé contenant un cycle substitué par des hétéro-atomes ou des groupes contenant des hétéro-atomes
Provided is an intervertebral disc therapeutic agent having favorable post-transplant engraftment. This intervertebral disc therapeutic agent contains scaffold-free artificial tissue in which synovium-derived mesenchymal stem cells form a three-dimensional structure.
NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (Japon)
Inventeur(s)
Mizuguchi, Hiroyuki
Kawai, Kanae
Inui, Tatsuya
Abrégé
Research on methods for selective differentiation induction from pluripotent stem cells to small intestine epithelium-like cells is underway. The present invention provides an excellent highly functional small intestine epithelium-like cell population that can be used stably in tests for multidrug metabolism and permeability, and also provides a highly efficient method for producing cells. The present invention involves a method for inducing differentiation from pluripotent stem cells to small intestine epithelium-like cells, the method including following steps 1) and 2). 1) A step of inducing differentiation of pluripotent stem cells into entodermal cells. 2) A step of culturing the entodermal cells in a system comprising CHIR99021 and then inducing differentiation into small intestine epithelium-like cells. A small intestine epithelium-like cell population can be more efficiently obtained by seeding the small intestine epithelium-like cells produced by the differentiation induction method on a base material for producing an organoid or on a base material for two-dimensional culture and culturing.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12N 1/00 - Micro-organismes, p.ex. protozoaires; Compositions les contenant; Procédés de culture ou de conservation de micro-organismes, ou de compositions les contenant; Procédés de préparation ou d'isolement d'une composition contenant un micro-organisme; Leurs milieux de culture
20.
CURED PRODUCT, SELF-HEALING MEMBER, ADHESIVE, CURED PRODUCT PRODUCTION METHOD, REPAIR METHOD, CURED PRODUCT DECOMPOSITION METHOD, AND MONOMER
Provided is a cured product obtained by curing a composition containing: a monomer A having an ethylenically unsaturated group and a host group in a molecule thereof, wherein the host group is a monovalent group obtained by removing one hydrogen atom or hydroxy group from cyclodextrin or a cyclodextrin derivative; a monomer B having a dynamic covalent bond in a molecule thereof; and a monomer C that may have the abovementioned dynamic covalent bond. In the cured product, at least one monomer selected from the group consisting of the monomer B and the monomer C can penetrate through the host group in a skewered manner, the monomer B and the monomer C each have, in a molecule thereof, at least two curable groups, which could react with the other type of curable group, and at least one set of the curable groups in the monomer B are coupled via the dynamic covalent bond. Thus, said cured product could exhibit excellent toughness and/or excellent strength.
C08G 59/40 - Macromolécules obtenues par polymérisation à partir de composés contenant plusieurs groupes époxyde par molécule en utilisant des agents de durcissement ou des catalyseurs qui réagissent avec les groupes époxyde caractérisées par les agents de durcissement utilisés
C09J 133/00 - Adhésifs à base d'homopolymères ou de copolymères de composés possédant un ou plusieurs radicaux aliphatiques non saturés, chacun ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par un seul radical carboxyle, o; Adhésifs à base de dérivés de tels polymères
21.
BONDED SHAPED BODY, AND METHOD FOR MANUFACTURING SAME
A bonded shaped body (1) comprises a disk portion (10) and a first blade portion (20) that is linear friction bonded to the disk portion (10). A structural body having the same shape as the bonded shaped body (1) and formed integrally by being carved from one solid block (100) of the same type of material as the first blade portion (20) serves as a comparison structural body (101). The first blade portion (20) has a homogeneous material structure exhibiting a longer cold-dwell fatigue life than that of the comparison structural body (101).
B23K 20/12 - Soudage non électrique par percussion ou par une autre forme de pression, avec ou sans chauffage, p.ex. revêtement ou placage la chaleur étant produite par friction; Soudage par friction
22.
MOLECULAR MEMORY, METHOD FOR MANUFACTURING MOLECULAR MEMORY, METHOD FOR DECODING MOLECULAR MEMORY, AND DEVICE FOR DECODING MOLECULAR MEMORY
The present invention addresses the problem of providing a molecular memory suitable for reading in a unit of a single molecule, a method for manufacturing the molecular memory, a method for decoding the molecular memory, and a device for decoding the molecular memory. Said problem is solved by a molecular memory comprising: an address region; and a memory region linked to the address region. The address region and the memory region are formed of molecules that generate tunnel current. The memory region is formed of four or more types of molecules selected from a first molecule group. The address region is composed of four or more types of molecules selected from a second molecule group. The molecules included in the first molecule group are either of types totally different from the types of molecules included in the second molecule group, or include both types that are the same and different with respect to the types of molecules included in the second molecule group. As a result, the molecules forming the address region and the molecules forming the memory regions are partially of different types.
[Problem] The present invention addresses the problem of providing an end effector, etc., with which it is possible to resolve the problem of finger jamming, in which an operation part collides with a surface on which an object is placed and becomes uncontrollable. [Solution] One embodiment of the present invention provides an end effector. The end effector comprises an operation part, a support body, and a detection surface. The operation part is configured to project toward one end, thereby coming into contact with an object. The support body is configured to flexibly support the operation part so that the position and/or orientation of the operation part is displaced when force generated due to contact between the operation part and the object is received. The detection surface is located at the other end of the operation part relative to the one end, the detection surface being configured to not come into contact with the object, and the position and/or orientation of the detection surface being displaced together with that of the operation part. In a state in which the end effector is attached to a robot arm, the detection surface is disposed so as to face a sensor that is capable of measuring the position and/or orientation of the detection surface.
B25J 15/08 - Têtes de préhension avec des éléments en forme de doigts
G01L 5/16 - Appareils ou procédés pour la mesure des forces, du travail, de la puissance mécanique ou du couple, spécialement adaptés à des fins spécifiques pour la mesure de plusieurs composantes de la force
24.
HEAT CONDUCTIVE JOINING STRUCTURE, HEAT CONDUCTIVE JOINING METHOD, HEAT SINK HAVING SAID HEAT CONDUCTIVE JOINING STRUCTURE, AND SEMICONDUCTOR DEVICE HAVING SAID HEAT CONDUCTIVE JOINING STRUCTURE
[Problem] To provide a heat conductive joining technology which is suitable for a joining structure of a semiconductor device, is capable of mitigating stress due to thermal deformation and preventing damage and peeling of a joining part, ensures low thermal resistance, and is capable of enhancing heat dissipation through heat transfer between members, and With which it is possible to maintain durability as a device without maintaining stiffness between the members in the stacking direction thereof, and maintain parallelism between the members during joining and assembly to enhance assembly accuracy. [Solution] This structure, which is composed of a joining layer 10 which is in close contact with a member 9 and performs heat transfer between the structure and the member 9, comprises: a metal-made porous base plate 11 having a plurality of through-holes 111 which extend in the thickness direction of the plate and are open in the front and rear plate surfaces of the plate; and a solder solidified body 12 composed of a filling part 121 filled in the though-holes 111 of the porous base plate 11, and solder films 122, 123 which are continuous to the filling part and expand on at least one plate surface, wherein the structure is brought into close contact with and joined to the facing member 9 by means of the solder film 122.
Provided are: a combination of a DNA construct comprising a first site-specific recombinase gene disposed so as to be capable of acting on a promoter of a first gene specific to a specified cell through a DNA construct comprising an n-th site-specific recombinase gene disposed so as to be capable of acting on a promoter of an n-th gene specific to said cell and a DNA construct comprising a killing gene disposed so as to be capable of acting on a constitutive promoter and in which each of transcriptional termination sequences disposed between sequences recognized and excised by the first through n-th site-specific recombinases is disposed between the constitutive promoter and the killing gene; a cell into which said combination has been introduced; and a non-human organism comprising said cell.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12N 1/15 - Champignons; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - Levures; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
26.
HEART FAILURE TREATMENT VIA CARDIOTONIC EFFECT BY TRPC3/6/7 CHANNEL ACTIVATION
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES (Japon)
OSAKA UNIVERSITY (Japon)
KYOTO UNIVERSITY (Japon)
SHINSHU UNIVERSITY (Japon)
Inventeur(s)
Nishida, Motohiro
Nishiyama, Kazuhiro
Kato, Yuri
Nishimura, Akiyuki
Nagata, Ryu
Mori, Yasuo
Nakagawa, Yasuaki
Kuwahara, Koichiro
Abrégé
Provided is a drug for preventing or treating heart failure, that is effective and that does not have a blood pressure lowering effect. The present invention pertains to: a pharmaceutical composition for preventing or treating heart failure or skeletal muscle failure, the pharmaceutical composition containing a TRPC3/6/7 channel activator; and a related screening method.
A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
A61P 9/04 - Agents inotropes, c. à d. stimulants de la contraction cardiaque; Médicaments pour le traitement de l'insuffisance cardiaque
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
C07D 401/00 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
27.
METHOD FOR MANUFACTURING THREE-DIMENSIONAL SHAPED ARTICLE AND INSET FOR PRODUCTION OF THREE-DIMENSIONAL SHAPED ARTICLE
The present invention provides a method for manufacturing a three-dimensional shaped article and an inset for production of a three-dimensional shaped article which make it possible to produce a three-dimensional shaped article with good shaping precision, even when producing a three-dimensional shaped article that has a complex shape and that is made from a soft material, for example. The present invention relates to a method for manufacturing a three-dimensional shaped article, said method comprising: a step for respectively discharging (a) a model material ink which contains a photo-crosslinkable polymer and (b) a support material ink which contains a support material and a first crosslinking factor; a step for photo-curing the discharged photo-crosslinkable polymer; and a step for removing a molded article of the support material ink.
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
B29C 64/112 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant des gouttelettes individuelles, p.ex. de buses de jet
The present invention addresses the problem of providing a compound and pharmaceutical composition that possesses inhibitory activity against the drug efflux pumps of drug-resistant bacteria and, when used in combination with another drug, can restore the antibacterial activity of said other drug. The present invention provides a compound represented by general formula [1] (the symbols are as defined in the description) or a salt thereof and a pharmaceutical compound comprising these.
C07D 211/34 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
C07D 211/14 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux ne contenant que des atomes de carbone et d'hydrogène liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
C07D 211/22 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre liés par des liaisons simples par des atomes d'oxygène
C07D 211/26 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'azote
C07D 211/46 - Atomes d'oxygène liés en position 4 comportant un atome d'hydrogène comme second substituant en position 4
C07D 211/48 - Atomes d'oxygène liés en position 4 comportant un atome de carbone acyclique lié en position 4
C07D 211/62 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile liés en position 4
C07D 211/70 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
C07D 213/36 - Radicaux substitués par des atomes d'azote liés par des liaisons simples
C07D 277/28 - Radicaux substitués par des atomes d'azote
C07D 305/08 - Composés hétérocycliques contenant des cycles à quatre chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle non condensés avec d'autres cycles ne comportant pas de liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes du cycle
C07D 307/52 - Radicaux substitués par des atomes d'azote ne faisant par partie d'un radical nitro
C07D 307/79 - Benzo [b] furannes; Benzo [b] furannes hydrogénés avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
C07D 319/18 - Ethylènedioxybenzènes, non substitués sur l'hétérocycle
C07D 333/20 - Radicaux substitués par des hétéro-atomes, autres que les halogènes, liés par des liaisons simples par des atomes d'azote
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 409/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 409/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
The purpose of the present invention is to simplify the configuration of a signal detection device. The signal detection device (100) comprises: a resonant tunneling diode (RTD) that emits terahertz waves at an object (TG), and receives the terahertz waves reflected by the object (TG) and thereby outputs an output signal; a detection unit (20A) for detecting the output signal from the RTD (1); and a voltage supply unit (11A) for supplying an AC voltage and a DC voltage to the RTD (1).
G01S 7/4911 - DÉTERMINATION DE LA DIRECTION PAR RADIO; RADIO-NAVIGATION; DÉTERMINATION DE LA DISTANCE OU DE LA VITESSE EN UTILISANT DES ONDES RADIO; LOCALISATION OU DÉTECTION DE LA PRÉSENCE EN UTILISANT LA RÉFLEXION OU LA RERADIATION D'ONDES RADIO; DISPOSITIONS ANALOGUES UTILISANT D'AUTRES ONDES - Détails des systèmes correspondant aux groupes , , de systèmes selon le groupe - Détails des systèmes non pulsés Émetteurs
G01N 21/3581 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant un rayonnement térahertz
G01S 13/89 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques pour la cartographie ou la représentation
G01S 17/89 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour la cartographie ou l'imagerie
H03B 7/08 - Production d'oscillations au moyen d'un élément actif ayant une résistance négative entre deux de ses électrodes avec un élément déterminant la fréquence comportant des inductances et des capacités localisées l'élément actif étant un dispositif à semi-conducteurs l'élément actif étant une diode tunnel
30.
FRICTION STIR WELDING METHOD AND FRICTION STIR WELDING TOOL
This friction stir welding method causes a friction stir welding tool to pass through a material to be welded, in the thickness direction of the material to be welded, and performs friction stir welding in a state in which a refrigerant is flowing through a through-hole provided in a rotating shaft of the friction stir welding tool.
B23K 20/12 - Soudage non électrique par percussion ou par une autre forme de pression, avec ou sans chauffage, p.ex. revêtement ou placage la chaleur étant produite par friction; Soudage par friction
31.
METHOD FOR CULTURING CANCER ORGANOID AND METHOD FOR SCREENING TEST SUBSTANCE
This method for culturing a cancer organoid includes culturing the cancer organoid on the top surface or inside of a cell structure in a medium free from extracellular matrix, wherein the cell structure contains cells constituting the stroma and two or more cell layers are laminated in the thickness direction therein. The method for screening a test substance includes culturing a cell structure containing a cancer organoid, which is obtained by the aforesaid method for culturing a cancer organoid, in the presence of a test substance, and evaluating the effect of the test substance on the cancer organoid.
C12N 1/00 - Micro-organismes, p.ex. protozoaires; Compositions les contenant; Procédés de culture ou de conservation de micro-organismes, ou de compositions les contenant; Procédés de préparation ou d'isolement d'une composition contenant un micro-organisme; Leurs milieux de culture
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
According to an embodiment, the present disclosure provides a modified luciferase having improved luminescence intensity, and a use thereof. The present disclosure relates to a modified luciferase derived from a luminous mushroom, or a functional fragment thereof in which a mutation is introduced into at least one among arginine or lysine corresponding to position 26 and valine corresponding to position 161 in the amino acid sequence indicated by SEQ ID NO: 1, and which has an enhanced luminescence compared with the luminescence before the introduction of the mutation. The present disclosure also relates to an isolated nucleic acid encoding the modified luciferase or a functional fragment thereof.
A01H 5/00 - Angiospermes, c. à d. plantes à fleurs, caractérisées par leurs parties végétales; Angiospermes caractérisées autrement que par leur taxonomie botanique
C12N 15/31 - Gènes codant pour des protéines microbiennes, p.ex. entérotoxines
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
33.
SENSOR, METHOD FOR MANUFACTURING SENSOR, AND INFORMATION PROCESSING METHOD
[Problem] To provide a high precision sensor having a simpler structure. [Solution] According to one aspect of the present invention, a sensor for measuring objects is provided. The sensor comprises a plurality of light-emitting elements and at least one light-receiving element. The light-emitting elements are each provided at a different position on a substrate. The light-receiving element is provided on the substrate. The light-receiving element receives, as main light, one reflected light from among reflected light attributed to each light-emitting element, and receives, as crosstalk light, reflected light other than the main light in a manner such that the crosstalk light can be distinguished from the main light. The reflected light is emitted from each of the light-emitting elements and reflected from an object. On the basis of the crosstalk light and main light that are received in a distinguishable manner, spatial physical quantities related to a reference plane of the sensor and the object are measured.
The present invention addresses the problem of providing a novel composition for cartilage repair including cells that have characteristics suitable for cartilage repair, and a method for producing same. With a focus on umbilical cord tissue-derived cells, three-dimensional culturing of umbilical cord tissue-derived cells was carried out. It was found that umbilical cord tissue-derived cells constituting a culture obtained by three-dimensional culturing have cell proliferation ability and gene expression level characteristics different from those of cells constituting a culture obtained by three-dimensional culturing of cells derived from other tissues. The umbilical cord tissue-derived cells constituting a culture obtained by three-dimensional culturing of the present invention have characteristics suitable for cartilage repair and make it possible to provide a composition effective for cartilage repair.
It was found that administering a composition containing cancer cells that express damage-associated molecular patterns (DAMPs) to a subject using a needleless syringe causes the cancer cells in the composition to be damaged by shear force at the time of administration and the DAMPs to be released from the cells, whereby cell-mediated immunity is efficiently activated.
STROOP TEST METHOD, STROOP TEST PROGRAM, STROOP TEST SYSTEM, STROOP TEST IMAGE GENERATION METHOD, STROOP TEST IMAGE GENERATION PROGRAM, AND TEST METHOD
In this Stroop test method, an evaluation of a subject is indicated on the basis of line-of-sight position information indicating the position of the line-of-sight of the subject in a test image (S102-S105). The test image has a question region in which a question for the subject is displayed, and an answer region in which a plurality of options for the subject to select to answer the question by means of the line-of-sight are displayed, the plurality of options including a correct option and one or more incorrect options. The one or more incorrection options include a decoy option that a subject may be guided to by the Stroop effect.
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
A61B 3/113 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
G06F 3/0346 - Dispositifs de pointage déplacés ou positionnés par l'utilisateur; Leurs accessoires avec détection de l’orientation ou du mouvement libre du dispositif dans un espace en trois dimensions [3D], p.ex. souris 3D, dispositifs de pointage à six degrés de liberté [6-DOF] utilisant des capteurs gyroscopiques, accéléromètres ou d’inclinaiso
37.
INORGANIC STRUCTURE AND METHOD FOR PRODUCING INORGANIC STRUCTURE
Provided are an inorganic structure including portions differing in mechanical property and a method for producing the inorganic structure. An inorganic structure (1) as an embodiment of the present invention comprises a plurality of solidified portions (SA) made of an inorganic material. The plurality of solidified portions (SA) comprise a first solidified portion (SA1), in which the material has been oriented preferentially in a first crystallographic orientation (CO1), and a second solidified portion (SA2), in which the material has been oriented preferentially in a second crystallographic orientation (CO2), which differs from the first crystallographic orientation (CO1).
B22F 10/38 - Commande ou régulation des opérations pour obtenir des caractéristiques spécifiques du produit, p.ex. le lissage de la surface, la densité, la porosité ou des structures creuses
B22F 10/28 - Fusion sur lit de poudre, p.ex. fusion sélective par laser [FSL] ou fusion par faisceau d’électrons [EBM]
B28B 1/30 - Fabrication d'objets façonnés à partir du matériau en appliquant le matériau sur un noyau ou une autre surface de moulage pour former une couche sur celle-ci
B33Y 80/00 - Produits obtenus par fabrication additive
38.
SYSTEM FOR DETERMINING DEPRESSION RISK USING FUNDUS IMAGE, MACHINE LEARNING MODEL GENERATION DEVICE, DEPRESSION RISK DETERMINATION DEVICE, AND DEPRESSION RISK DETERMINATION METHOD
Provided is a depression risk determining system with which it is possible to determine the risk of depression from a fundus image. The system for determining depression risk according to the present invention comprises: a machine learning model generation device that generates a trained model for determining the risk of depression; and a depression risk determination device that determines the risk of depression by using the trained model generated by the machine learning model generation device. The machine learning model generation device includes a data acquisition unit that acquires at least inquiry data for training and a fundus image for training, and a machine learning model generation unit that generates a trained model. The depression risk determination device includes a determination data acquisition unit that acquires a fundus image used for determination, a depression risk determination unit that inputs at least the fundus image used for determination to the trained model to thereby output a prediction score indicating depression risk, and a determination result output unit that outputs the determination results of depression risk on the basis of the prediction score.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
To develop a new tumor preventative/therapeutic. Provided are: an agent for preventing and/or treating a tumor, the agent containing, inter alia, an IKZF1ΔE5 protein, which is a deletion variant of IKZF1 in which part or all of exon 5 has been deleted, or an IKZF1ΔE5-gene-related substance; and a method for screening such agents.
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
40.
AROMATIC COMPOUND, MIXTURE, MOLECULAR PROBE FOR HYPERPOLARIZATION, METABOLITE, DIAGNOSTIC AGENT, DERIVATIZATION AGENT, NAPHTHALENE DERIVATIVE, CATECHOL DERIVATIVE, AND COMPOUND
An aromatic compound configured from a stable isotope, wherein two adjacent carbon atoms are 13C, the nuclear spin quantum number of the other atoms to which the two adjacent carbon atoms bond is 0, and a hydrogen atom that has a spin coupling constant and bonds with the 13C nucleus via a carbon atom is substituted with a deuterium atom. In this aromatic compound, the relaxation time of the 13C nucleus excited by a DNP device is longer than in the past.
A61K 31/136 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p.ex. benzène-amine
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07C 11/22 - Hydrocarbures non saturés acycliques comportant des liaisons triples carbone-carbone
C07C 33/34 - Alcools monohydroxyliques contenant des cycles aromatiques à six chaînons et d'autres cycles
C07C 47/12 - Composés saturés comportant des groupes —CHO liés à des atomes de carbone acycliques ou à de l'hydrogène contenant plus d'un groupe —CHO
C07C 211/58 - Naphtylamines; Leurs dérivés N-substitués
C07C 229/36 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons avec au moins un groupe amino et un groupe carboxyle liés au même atome de carbone du squelette carboné
C07C 255/04 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone acycliques d'un squelette carboné acyclique et saturé contenant deux groupes cyano liés au squelette carboné
The purpose of the present invention is to provide a method for manufacturing a layered structure in which it is easy to control the crystal structure in the layered structure. A method for manufacturing a layered structure is selected in which: a gas flow parallel to the surface of a powder bed is provided; an energy beam is radiated while being scanned in a first direction to form a first melt-solidified layer; an energy beam is radiated while being scanned in a second direction intersecting the first direction to form a second melt-solidified layer; a first accumulation thickness of the powder bed and a first heat input amount of the energy beam are adjusted to control the layering thickness of the first melt-solidified layer and the penetration depth of the first melt-solidified layer; a second accumulation thickness of the powder bed and a second heat input amount of the energy beam are adjusted to control the layering thickness of the second melt-solidified layer and the penetration depth of the second melt-solidified layer; the angle α1 between the first direction and the gas flow direction is adjusted to control the first heat input amount; the angle α2 between the second direction and the gas flow direction is adjusted to control the second heat input amount; and the residual thickness of the first melt-solidified layer and the residual thickness of the second melt-solidified layer in the crystal structure are controlled.
B22F 10/322 - Commande ou régulation des opérations de l’atmosphère, p.ex. de la composition ou de la pression dans une chambre de fabrication d’un écoulement de gaz, p.ex. du débit ou de la direction
B22F 10/28 - Fusion sur lit de poudre, p.ex. fusion sélective par laser [FSL] ou fusion par faisceau d’électrons [EBM]
B22F 10/366 - Paramètres de balayage, p.ex. distance d’éclosion ou stratégie de balayage
B22F 10/38 - Commande ou régulation des opérations pour obtenir des caractéristiques spécifiques du produit, p.ex. le lissage de la surface, la densité, la porosité ou des structures creuses
Provided is a method for producing high-quality group III nitride crystals through a flux method. This method for producing group III nitride crystals includes bringing a melt that includes an alkali metal and at least one group III element selected from gallium, aluminum, and indium into contact with the surface of group III nitride seed crystals in a nitrogen-containing atmosphere, thereby reacting the group III element and nitrogen within the melt to grow group III nitride crystals on the group III nitride seed crystals, wherein: the method includes a nucleus generation step for growing a plurality of island-form group III nitride crystal nuclei on the surface of group III nitride seed crystals, a first crystal growth step for growing first group III nitride crystals, each of which has an inverted triangular or trapezoidal cross-section, from the plurality of island-form group III nitride crystal nuclei, and a second crystal growth step for growing second group III nitride crystals so that hollows in the first group III nitride crystals are filled and the surface becomes flat; in the nucleus generation step for growing a plurality of island-form group III nitride crystal nuclei, the temperature is 875°C or higher, and the nucleus generation density is 1×106/cm2 or lower; and the first and second crystal growth steps include repeatedly immersing the group III nitride seed crystals in the melt and lifting the group III nitride seed crystals from the melt a plurality of times.
C30B 19/04 - Croissance d'une couche épitaxiale à partir de la phase liquide en utilisant des solvants fondus, p.ex. des fondants le solvant étant un constituant du cristal
43.
METHOD FOR MEASURING MINERALOCORTICOID RECEPTOR ACTIVITY
[Problem] A mineralocorticoid receptor (MR) is activated due to various pathoses, and the excessive activation thereof is a risk factor of the onset of cerebrocardiovascular diseases. However, since there are no indicators for directly evaluating MR activity, the early detection of excessive MR activation is difficult. The present invention addresses the problem of finding out indicators capable of directly evaluating MR activity. [Solution] It has been found that MR activity can be directly evaluated by using, as an indicator, the protein amount in an epithelial sodium channel (ENaC) subunit contained in a urinary extracellular vesicle. The indicator is preferably the ratio of the protein amount in the ENaC subunit to the internal control protein amount in the extracellular vesicle. The ratio (γENaC/CD9) of ENaCγ subunit to CD9 is exemplified as a specific aspect thereof. Using the indicator makes it possible to start early treatment by examining diseases related to MR activation. The start of early treatment makes it possible to prevent the onset of cerebrocardiovascular diseases.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
44.
METHOD FOR CHECKING POSSIBILITY OF LIVER CANCER ONSET
Provided is a method for checking the possibility of liver cancer onset. This method for checking the possibility of liver cancer onset comprises (1) a step for detecting at least one type of molecules of interest selected from the group consisting of Fibulin 3, GPNMB, Fibulin 3 mRNA, and GPNMB mRNA in a biological sample collected from a subject.
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
45.
PREDICTION DEVICE, PREDICTION METHOD, AND PREDICTION PROGRAM
NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY (Japon)
OSAKA UNIVERSITY (Japon)
Inventeur(s)
Majima, Kei
Yahata, Noriaki
Yanagisawa, Takufumi
Fukuma, Ryohei
Kishima, Haruhiko
Shiraishi, Yoshiyuki
Kawahara, Yoshinobu
Yamashita, Okito
Abrégé
Provided are a prediction device, a prediction method, and a prediction program that can make predictions from multidimensional time series data at high speed and with high accuracy. A prediction device 1, which analyzes multidimensional time series data regarding a predetermined event, and predicts events from the multidimensional time series data, includes a predictive means for acquiring multidimensional time series data, decomposes the multidimensional time series data into matrix data using dynamic mode decomposition, acquires features from the matrix data, acquires predicted values from the features and weights calculated in advance on the basis of the kernel method, and predicts events from the predicted values.
NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (Japon)
OSAKA UNIVERSITY (Japon)
Inventeur(s)
Yokota Takanori
Yoshioka Kotaro
Matsubayashi Taiki
Obika Satoshi
Nakagawa Osamu
Abrégé
The present invention addresses the problem of providing a novel nucleic acid drug capable of simultaneously achieving both a high gene regulatory effect and a low toxicity. Provided is a toxicity reducing agent for a nucleic acid drug that comprises a nucleoside containing an artificial base represented by formula (I), said toxicity reducing agent being linked to a nucleic acid chain constituting the nucleic acid drug via an internucleoside linkage.
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique
A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c. à d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c. à d. autres que le ribose ou le 2'-désoxyribose
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c. à d. autres que des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (Japon)
Inventeur(s)
Mizuguchi Hiroyuki
Sakurai Fuminori
Kamada Haruhiko
Abrégé
Provided is a human Ad 5 vector etc., capable of avoiding immune response by existing antibody. The present invention is based on human adenovirus type 5 and pertains to a hexon-modified adenovirus vector in which the amino acid sequence of at least one hypervariable region (HVR) among HVR1 through HVR7 present in the hexon region has been modified.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
The present invention provides a method for manufacturing a three-dimensional object and an ink set for manufacturing a three-dimensional object, whereby it is possible to manufacture a three-dimensional object with good modeling accuracy, for example, even when manufacturing a complex-shaped three-dimensional object made of soft materials. The present invention pertains to a method for manufacturing a three-dimensional object, the method comprising the steps of: discharging (a) a modelling material ink containing a crosslinkable polymer and (b) a support material ink containing a support material, respectively; and removing an object from the support material ink after crosslinking the crosslinkable polymer, wherein either one of the modelling material ink (a) and the support material ink (b) further contains a hydrogen peroxide decomposer, the other further contains hydrogen peroxide or a hydrogen peroxide donor, and the discharged hydrogen peroxide decomposer decomposes discharged hydrogen peroxide and crosslinks the crosslinkable polymer, thereby creating a three-dimensional object.
B29C 64/112 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant des gouttelettes individuelles, p.ex. de buses de jet
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
Provided are: a pharmaceutical composition for treating damage to the white-white zone or red-white zone of the meniscus, said composition containing an HMGB1 fragment peptide containing an amino acid sequence delimited by SEQ ID NO 1, or a variant thereof; and a pharmaceutical composition for treating a meniscus excision site, said composition containing an HMGB1 fragment peptide containing an amino acid sequence delimited by SEQ ID NO 1, or a variant thereof.
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
A61P 19/04 - Médicaments pour le traitement des troubles du squelette des troubles non-spécifiques du tissu conjonctif
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
50.
VIBRATION COMPONENT MEASURING DEVICE, KELVIN PROBE FORCE SPECTROMETER, VIBRATION COMPONENT MEASURING METHOD, AND INTERFACE STATE DENSITY MEASURING METHOD
In order to measure a change in a fluctuating component of a vibrating unit more efficiently, and to calculate an interface state density of a sample more efficiently, a vibration component measuring device (2) comprises: a vibrating unit (4); a vibration control unit (10) for causing the vibrating unit to vibrate on the basis of a first alternating current signal; a signal applying unit (14, 48) for applying at least one of a direct current signal, a second alternating current signal, and a reference alternating current signal between the vibrating unit and a sample; and a measuring unit (42, 44) for measuring a fluctuating component of the vibration of the vibrating unit. The measuring unit measures a change in the fluctuating component with respect to a change in a voltage value of the direct current signal.
A purpose of the present invention is to provide an alginic acid salt superior in hemostatic effect to conventional alginic acid salts. This alginic acid salt has a carboxyl-group calcium salt and another carboxyl (salt) group, and is characterized in that, when structural units containing the calcium salt group, among the repeating units (structural units) constituting the alginic acid salt, are referred to as calcium alginate and structural units containing the other carboxyl (salt) group are referred to as sodium alginate and when the alginic acid salt is regarded as a mixture of the sodium alginate and the calcium alginate, then the mass proportion (calcium content) of the calcium alginate is 1-99 mass%.
Provided are a new sulfur-containing polymer and a method for producing the same, a composition containing the new sulfur-containing polymer, and a sulfur-containing compound. A sulfur-containing high molecular weight compound according to the present invention has a structural unit represented by, for example, general formula (1) -R1-R-R1nn- (in formula (1), n represents a number of 1 or more, R represents an organic group, and R1 represents a divalent organic group derived from a functional group that can undergo polycondensation). A method for producing a sulfur-containing high molecular weight compound according to the present invention comprises a step for obtaining the sulfur-containing high molecular weight compound by reacting a linear sulfur polymer and a compound C having two functional groups that can undergo polycondensation.
The purpose of the present invention is to realize a Faraday rotator that is small, inexpensive, and can withstand high-output and high-repetition laser radiation. An optical element (100) includes: a reflective Faraday rotation element (110) that rotates the polarization plane of reflected light with respect to the polarization plane of incident light; a magnet (130) provided on the opposite side of the plane onto which the incident light falls with respect to the Faraday rotation element; and a coolant circulation unit (140) and/or a cryostat (150) that cools the Faraday rotation element.
G02B 27/28 - Systèmes ou appareils optiques non prévus dans aucun des groupes , pour polariser
G02F 1/09 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p.ex. commutation, ouverture de porte ou modulation; Optique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des éléments magnéto-optiques, p.ex. produisant un effet Faraday
54.
SYSTEM FOR IDENTIFYING FACIAL EXPRESSION OF PERSON
Provided is a system for identifying facial expression of a person, the system being capable of identifying the facial expression of a person by using extension/contraction of a mask that people wear on a daily basis, and also reflect the facial expression in a motion or expression of an avatar face in a virtual space. The system comprises: a plurality of detection means 4 which are disposed in a mask 3 and include sensors that detect extension/contraction or distortion of the mask 3; a storage means 2 which stores training data that is obtained through machine learning a correspondence relationship between shape variation amounts at the respective portions of the mask 3, which are detected in the plurality of detection means 4, and a facial motion or facial expression accompanying the motion, or is obtained as a mathematical model; and an identification means 14 which compares the shape variation amounts detected in the plurality of detection means 4 and the training data and identifies the facial expression of a person.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japon)
Inventeur(s)
Kishimoto Tadamitsu
Metwally Hozaifa Saad Hassan
Ozawa Tatsuhiko
Abrégé
The present invention provides: a sepsis and/or septic shock therapeutic agent containing, as an active ingredient, a compound that suppresses phosphorylation of threonine at position 749 of human STAT1; a method for screening a candidate compound for an active ingredient of a sepsis and/or septic shock therapeutic agent including a step for selecting a compound that suppresses phosphorylation of threonine at position 749 of human STAT1; a colitis treatment agent containing, as an active ingredient, a compound that promotes phosphorylation of threonine at position 749 of human STAT1; a method for screening a candidate compound for an active ingredient of a colitis treatment agent including a step for selecting a compound that promotes phosphorylation of threonine at position 749 of human STAT1; a systemic lupus erythematosus treatment agent containing, as an active ingredient, a compound that inhibits human STAT1; and a method for screening a candidate compound for an active ingredient of a systemic lupus erythematosus treatment agent including a step for selecting a compound that inhibits human STAT1.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p.ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
The present invention realizes a reservoir calculation system capable of self-holding of an activity for a long time at a low calculation cost. The present invention comprises: an input layer (10) to which an input signal is input; a reservoir (20) which includes a plurality of modules (22) containing a plurality of units (21) to which the input signal is input; an output layer (30) which generates an output signal on the basis of output from the plurality of modules; and a learning unit (40) which adjusts a parameter used in the output layer. The plurality of units are connected to each other in each module. At least the plurality of modules are in a limit cycle or a trace mode.
Provided are a fuel pellet capable of being mass-produced, and a fuel pellet production method. A fuel pellet (10) comprises a fusion fuel (11) and a spherical shell membrane (12) in which the fusion fuel is accommodated, wherein the inside of the membrane (12) is filled with the fusion fuel (11) in a liquid or solid state.
This electrostimulation device MA comprises a first electrode unit 10 including a negative electrode 11 and positive electrodes 12, 12, and a second electrode unit 20 including a negative electrode 21 and positive electrodes 22, 22. A medium-frequency AC current is fed, from an electrical circuit unit CI, between the negative electrode 11 and each of the positive electrodes 12, 12, and between the negative electrode 21 and each of the positive electrodes 22, 22. The negative electrode 11 and one of the positive electrodes 12, 12, and the negative electrode 21 and one of the positive electrodes 22, 22, are disposed on skin surface positions flanking one of a pair of deep muscles to be stimulated, and the negative electrode 11 and the other positive electrode 12, and the negative electrode 21 and the other positive electrode 22, are disposed on skin surface positions flanking the other of the pair of deep muscles to be stimulated. A medium-frequency current is thereby selectively boosted in deep parts and deep muscles are stimulated in an efficient manner.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
59.
PHARMACEUTICAL COMPOSITION AND AUTOPHAGY ACTIVATOR
The purpose of the present invention is to provide a pharmaceutical composition for treating or preventing diseases such as pulmonary diseases (excluding pulmonary fibrosis), renal diseases (excluding renal fibrosis), reproductive dysfunction, liver damage, eye diseases, skin diseases, cancer (excluding lung cancer, prostate cancer, and breast cancer), bacterial infection, viral infection, autoimmune diseases, metabolic syndrome, musculoskeletal diseases (excluding muscular dystrophy), and the like. The present invention pertains to a pharmaceutical composition that contains at least one compound selected from the group consisting of cannabidiol and compounds represented by formula (1), or a pharmaceutically acceptable salt thereof, and that is for treating or preventing at least one disease selected from the group consisting of pulmonary diseases (excluding pulmonary fibrosis), renal diseases (excluding renal fibrosis), reproductive dysfunction, liver damage, eye diseases, skin diseases, cancer (excluding lung cancer, prostate cancer, and breast cancer), bacterial infection, viral infection, autoimmune diseases, metabolic syndrome, musculoskeletal diseases (excluding muscular dystrophy), and the like.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p.ex. pipérazine
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
[Problem] To provide a drive control device capable of achieving high-density mount and integration of quantum bit elements used to execute an arithmetic operation by a quantum computer. [Solution] The present invention comprises a local oscillator and a quadrature mixer that applies the quadrature modulation to an output signal of the local oscillator and I/Q signals and is characterized in that the quadrature mixer is an even harmonic quadrature mixer.
In the present invention, a power supply circuit for cold start (PS) comprises: clock generating circuits (10, 20) that generate an HOL clock from the output voltage of a harvester (EH); a DRV circuit group (30) in which the HOL clock is inputted to a DRV circuit (31), and n stages of DRV circuits that are provided with a capacitor (C) and a switch (M) and that boost and output the inputted NOL clock are connected in series; and a CP circuit group (40) in which the output voltage is inputted to a CP circuit (41), and n stages of CP circuits that are provided with a capacitor (C) and a switch (S) and that provide a twofold boost of the inputted output voltage and output the boosted voltage are connected in series. In the DRV circuit group, the boosted voltage from CP circuits (41 to 4n) of the CP circuit group is used to charge the capacitors (C) of DRV circuits (31 to 3n) of the respectively corresponding stage, the clock signal inputted from the preceding DRV circuit is superimposed on the boosted voltage via the capacitor (C), and the resulting voltage is outputted. This allows cold start to be performed at extremely low voltage by generating effective clock signals while using a simple circuit configuration.
H02M 3/07 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu sans transformation intermédiaire en courant alternatif par convertisseurs statiques utilisant des résistances ou des capacités, p.ex. diviseur de tension utilisant des capacités chargées et déchargées alternativement par des dispositifs à semi-conducteurs avec électrode de commande
H02M 3/00 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu
62.
PROGRAM, INFORMATION PROCESSING METHOD, AND INFORMATION PROCESSING DEVICE
Provided is a program, for example, with which it is possible to acquire information pertaining to a bodily tissue amount from an X-ray image accurately on the basis of a small number of cases. A computer acquires training data which includes an X-ray image of a site of interest and information pertaining to a bodily tissue amount obtained from a computed tomography (CT) image of the site of interest. Then, the computer generates a learning model that, when an X-ray image is input thereto, uses the acquired training data to output information pertaining to the bodily tissue amount of the site of interest in the X-ray image.
G06V 10/70 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique
63.
METHOD FOR PRODUCING LOW-MOLECULAR-WEIGHT POLYTETRAFLUOROETHYLENE
NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY (Japon)
Inventeur(s)
Tanaka, Takayuki
Satoh, Kazuyuki
Tsukamoto, Mitsuo
Oshima, Akihiro
Nagasawa, Naotsugu
Seito, Hajime
Yamasaki, Shota
Abrégé
The present invention provides a method for producing a low-molecular-weight polytetrafluoroethylene which has a small variation in the molecular weight. The present invention provides a method for producing a low-molecular-weight polytetrafluoroethylene, the method comprising a step (1) in which a low-molecular-weight polytetrafluoroethylene that has a melt viscosity of 1.0 × 102Pa∙s to 7.0 × 105 Pa∙s at 380°C is obtained by irradiating a high-molecular-weight polytetrafluoroethylene with radiation such that the ratio (maximum dose)/(minimum dose) of the maximum dose to the minimum dose is 1.55 or less.
Provided is an organ model for medical devices, with which exercises of catheter manipulation, endoscope manipulation, etc. can be stably performed without deformation or impairment of the organ model. The present invention is an organ model 100 for medical devices, wherein the organ model 100 is held in a state where a container 10 is filled with liquid; and a catheter can be inserted into the organ model 100 through an insertion parts 11a', 12a' provided to the container 10. The organ model 100 is characterized by comprising a soft member 100A that is provided with a held part held by the container 10, and a hard member 100B that is provided with a plate-shaped part 130 disposed on an inner surface of the container 10 and that can be integrated with the soft member 100A, the hard member 100B not being fixed to the container 10, being attachable to and detachable from the soft member 100A, and being positioned through connection with the soft member 100A.
The present invention pertains to a method for collecting stem cells from animal tissue, the method comprising a step in which at least a surface of the animal tissue is made to contact a cleaning liquid, wherein the cleaning liquid is a solution containing peracetic acid, hydrogen peroxide, and acetic acid.
Provided are novel anti-CCR8 antibodies. Said antibodies detect CCR8 expressed in tumor invasive Treg cells or the like and are useful for cancer diagnosis or companion diagnostics.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
Provided is a cognitive function evaluation system for evaluating the cognitive function of a subject. The cognitive function evaluation system (100) is provided with a movement detection unit (20), a reply detection unit (30), a measurement unit (50), and an evaluation unit (40). The movement detection unit (20) captures an image of a subject (SJ) who executes a given task and generates imaged data. The reply detection unit (30) detects a reply to a given cognitive question by the subject (SJ) who is executing the given task. The measurement unit (50) measures a brain wave of the subject (SJ). The evaluation unit (40) extracts a feature of the movement of the subject (SJ) from the imaged data, also extracts a feature of the reply by the subject (SJ) from the replies detected by the reply detection unit (30), and evaluates the cognitive function of the subject (SJ) on the basis of the feature of the movement, the feature of the reply and the brain wave. The given task includes: such an exercise task that a given exercise is imposed to the subject (SJ); and such an intellectual task that a reply to a given cognitive question is imposed to the subject (SJ).
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p.ex. tremblement de la tête ou des mains ou mobilité d'un membre
A61B 5/374 - Détection de la répartition de fréquence dans les signaux, p.ex. détection des ondes delta, thêta, alpha, bêta ou gamma
A61B 5/377 - Modalités, c. à d. méthodes diagnostiques spécifiques Électroencéphalographie [EEG] utilisant des réponses provoquées
68.
HEARING DEVICE, AND METHOD FOR MANUFACTURING HEARING DEVICE
A hearing device (1) can be disposed inside the body of a mammal. The hearing device (1) comprises a piezoelectric film (60), a plurality of recognition electrodes (30), an electrode layer (50), a substrate (20), and a surface layer (10). The piezoelectric film (60) converts oscillation into an electrical signal. The plurality of recognition electrodes (30) contact the piezoelectric film (60) on one side of a thickness direction (D2) of the piezoelectric film (60). The electrode layer (50) contacts the piezoelectric film (60) on another side of the thickness direction (D2) of the piezoelectric film (60). The substrate (20) has a long hole (21) and supports the piezoelectric film (60) with the electrode layer (50) interposed therebetween. The surface layer (10) covers the piezoelectric film (60) from the side opposite the electrode layer (50) and exposes at least a portion of each of the plurality of recognition electrodes (30). A width (w1) of the long hole (21) at one end in an extension direction (D1) is smaller than a width (w2) of the long hole (21) at another end in the extension direction (D1).
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61F 2/18 - Parties internes de l'oreille ou du nez, p.ex. tympans
A61F 11/00 - Procédés ou dispositifs pour le traitement des oreilles ou de l'ouie ; Prothèses auditives non électriques; Procédés ou dispositifs permettant au patient d’obtenir une perception auditive par des sens physiologiques autres que l’ouïe; Dispositifs de protection pour les oreilles, portés sur le corps ou dans la main
The present invention addresses the problems of providing a biomarker that serves as an indicator of susceptibility to an immune checkpoint inhibitor in liver cancer and providing suitable treatments for individual liver cancer patients. Liver cancer patients were stratified according to prognosis and tumor immune microenvironment, and a new relationship was clarified between fatty liver cancer and a tumor immune microenvironment that is immunopotentiating but also immunodepleting. Furthermore, fatty liver cancer patients were discovered to be susceptible to immunotherapy using immune checkpoint inhibitors. Employing the fat content in liver cancer tissue as an indicator of susceptibility to immune checkpoint inhibitors makes it possible to predict the success of an immune checkpoint inhibitor and to provide suitable treatments for individual liver cancer patients. The fat content can be calculated from an image of the liver cancer tissue or a signal for image display.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol
G16H 30/00 - TIC spécialement adaptées au maniement ou au traitement d’images médicales
70.
JOINED BODY, AND METHOD FOR MANUFACTURING JOINED BODY
The present disclosure provides a joined body in which copper and a cured product of a thermosetting composition are joined by a film, wherein: the film is formed from a thiol; the thiol is a prescribed compound having at least one first functional group selected from amino groups, carboxy groups, and hydroxyl groups; the thermosetting composition contains a thermosetting compound; and the thermosetting compound has a second functional group capable of reacting with the first functional group.
B32B 15/08 - Produits stratifiés composés essentiellement de métal comprenant un métal comme seul composant ou comme composant principal d'une couche adjacente à une autre couche d'une substance spécifique de résine synthétique
B32B 15/20 - Produits stratifiés composés essentiellement de métal comportant de l'aluminium ou du cuivre
The present invention provides a method for identifying a multifactorial interaction in a biological sample, said method comprising: (a) a step for selecting multiple factors to be analyzed; (b) a step for labeling an antibody molecule for each of the selected factors with a DNA barcode; (c) a step for bringing the biological sample containing the factors to be analyzed into contact with the antibody molecules labeled with the DNA barcodes; (d) a step for, after step (c), embedding the biological sample in a hydrogel; (e) a step for, in the hydrogel, performing a nucleic acid amplification reaction using multiple primers that are designed so as to, when two antibodies come close to each other, generate an amplification product containing both DNA barcode sequences; and (f) a step for analyzing the base sequence of the amplification product thus generated to detect the presence of a factor that is simultaneously interacting with two or more factors.
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p.ex. par des compteurs de colonies
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6804 - Analyse d’acides nucléiques utilisant des immunogènes
C12Q 1/6811 - Méthodes de sélection pour la production ou l’élaboration d’oligonucléotides spécifiques cibles ou de molécules de liaison
The present disclosure provides an antiprotozoal agent targeting a transcription factor. The present disclosure provides a pyrrole-imidazole polyamide (PIPA) specifically binding to a binding region of a protozoa transcription factor.
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/787 - Polymères contenant de l'azote contenant des hétérocycles ayant l'azote comme hétéro-atome d'un cycle
C07C 209/48 - Préparation de composés contenant des groupes amino liés à un squelette carboné par réduction d'acides carboxyliques ou de leurs esters en présence d'ammoniac ou d'amines ou par réduction de nitriles, d'amides d'acides carboxyliques, d'imines ou d'imino-éthers par réduction de nitriles
C07C 211/07 - Monoamines contenant un, deux ou trois groupes alkyle, chacun ayant le même nombre d'atomes de carbone supérieur à trois
C07C 211/17 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné saturé contenant des cycles autres que des cycles aromatiques à six chaînons ne contenant que des cycles non condensés
C07C 211/19 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné saturé contenant des cycles autres que des cycles aromatiques à six chaînons contenant des systèmes cycliques condensés
C07C 211/27 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant au moins un cycle aromatique à six chaînons ayant des groupes amino reliés au cycle aromatique à six chaînons par l'intermédiaire de chaînes carbonées saturées
C07C 211/29 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant au moins un cycle aromatique à six chaînons le squelette carboné étant substitué de plus par des atomes d'halogène ou par des groupes nitro ou nitroso
C07C 211/30 - Composés contenant des groupes amino liés à un squelette carboné ayant des groupes amino liés à des atomes de carbone acycliques d'un squelette carboné non saturé contenant au moins un cycle aromatique à six chaînons le cycle aromatique à six chaînons faisant partie d'un système cyclique condensé formé par deux cycles
C07C 217/58 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes hydroxy éthérifiés liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six avec des groupes amino reliés au cycle aromatique à six chaînons, ou au système cyclique condensé contenant ce cycle, par l'intermédiaire de chaînes carbonées qui ne sont pas substituées de plus par des atomes d'oxygène liés par des liaisons simples avec des groupes amino et le cycle aromatique à six chaînons, ou le système cyclique condensé contenant ce cycle, liés au même atome de carbone de la chaîne carbonée
C07C 321/28 - Sulfures, hydropolysulfures ou polysulfures ayant des groupes thio liés à des atomes de carbone de cycles aromatiques à six chaînons
74.
VASCULAR ENDOTHELIAL BARRIER FAILURE INHIBITOR AND USE THEREOF
This vascular endothelial barrier failure inhibitor contains, as an active ingredient, a claudin-5 expression inducer, a nucleic acid coding claudin-5, or claudin-5.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
C12N 15/12 - Gènes codant pour des protéines animales
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japon)
KYOEISHA CHEMICAL CO., LTD. (Japon)
Inventeur(s)
Takashima, Yoshinori
Park, Junsu
Tanaka, Masaru
Ueda, Tomoya
Araki, Kumiko
Takenaka, Naomi
Kure, Bunsho
Abrégé
The present invention improves the physical properties of a polymer that includes an alkoxy alkyl (meth)acrylate as a principal structural unit to achieve a polymer that has physical properties that are very similar to a biological substance. The present invention provides a copolymer that includes as structural units (A) a hydroxy alkyl (meth)acrylate and/or an alkoxy alkyl (meth)acrylate and (B) a monomer that has a host group.
C08F 220/26 - Esters contenant de l'oxygène en plus de l'oxygène de la fonction carboxyle
C08F 220/28 - Esters contenant de l'oxygène en plus de l'oxygène de la fonction carboxyle ne contenant pas de cycles aromatiques dans la partie alcool
C08F 220/58 - Amides contenant de l'oxygène en plus de l'oxygène de la fonction carbonamide
C08L 33/14 - Homopolymères ou copolymères des esters d'esters contenant des atomes d'halogène, d'azote, de soufre ou d'oxygène en plus de l'oxygène du radical carboxyle
C08L 33/26 - Homopolymères ou copolymères de l'acrylamide ou de la méthacrylamide
A61L 27/16 - Matériaux macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
Provided is a novel magnetostrictive material that has a high magnetostrictive property despite being rare-earth-free. This magnetostrictive material contains copper cobalt ferrite wherein cubic crystals are the primary crystal phase.
C04B 35/32 - Produits céramiques mis en forme, caractérisés par leur composition; Compositions céramiques; Traitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base d'oxydes à base de ferrites avec l'oxyde de cobalt comme oxyde principal
H01F 1/03 - Aimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriés; Emploi de matériaux spécifiés pour leurs propriétés magnétiques en matériaux inorganiques caractérisés par leur coercivité
The present invention provides: a production method for a conjunctival epithelial cell mass that is characterized by including (1) a step for inducing differentiation of conjunctival epithelial stem/precursor cells from pluripotent stem cells, (2) a step for collecting cells that express a conjunctival epithelium marker selected from the group that consists of BST2, SLC2A3, AGR2, TMEM54, OLR1, TRIM29, and CITED2 from the resulting conjunctival epithelial stem/precursor cells, and (3) a step for culturing and maturing the cells that express the conjunctival epithelial marker; a detection method for conjunctival epithelial cells that is characterized by detecting the cells of an eye surface epithelial cell mass that express a conjunctival epithelial cell marker selected from the group that consists of BST2, SLC2A3, AGR2, TMEM54, OLR1, TRIM29, and CITED2; and a method for improving the purity of conjunctival epithelial cells in an eye surface epithelial cell mass that is characterized by collecting cells that express a conjunctival epithelial marker selected from the group that consists of BST2, SLC2A3, AGR2, TMEM54, OLR1, TRIM29, and CITED2. The present invention can be used to produce conjunctival epithelial cell masses and to detect and improve the purity of conjunctival epithelial cells.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
78.
CALCULATION (EVALUATION) METHOD FOR ANCHORAGE STRENGTH OF MECHANICAL REBAR ANCHORAGE METHOD
NATIONAL UNIVERSITY CORPORATION TOYOHASHI UNIVERSITY OF TECHNOLOGY (Japon)
HORIE ENGINEERING AND ARCHITECTURAL RESEARCH INSTITUTE CO., LTD. (Japon)
Inventeur(s)
Sanada Yasushi
Matsui Tomoya
Sakuta Joji
Kiyohara Toshihiko
Adachi Tomohiro
Kim Yooheui
Abrégé
[Problem] To improve the accuracy of the estimated anchorage strength calculation in mechanical rebar anchorage. [Solution] A method for calculating an estimated anchorage strength Pn when an anchorage member 2 fails due to cone-type failure against tensile force T generated in a main reinforcement 11, in the mechanical rebar anchorage where the main reinforcement 11 with anchorage hardware 40 attached to the end is disposed in the reinforced concrete structural anchorage member 2 and is anchored by the anchorage hardware 40. The anchorage strength Pn is calculated on the basis of the value obtained by multiplying the area of the side surface of a conical shape 50, which is assumed as the failure shape of the cone-type failure, by the tensile strength of the concrete against the cone-type failure.
The present invention provides: an anti-netrin-4 antibody capable of recognizing, as an epitope, an amino acid sequence (SEQ ID NO: 2) lying between position-192 to position-202 in an amino acid sequence (SEQ ID NO: 1) for human netrin-4; and a pharmaceutical composition for preventing or treating pain, which contains the antibody or a functional fragment thereof as an active ingredient.
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
C12N 1/15 - Champignons; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - Levures; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
[Problem] To clarify the mechanism of the medial olivocochlear (MOC) feedback system and provide a composition for preventing or treating auditory disorders in which MOC neurons participate. To provide a method for screening a compound for preventing or treating auditory disorders in which MOC neurons participate. [Solution] A composition for preventing or treating sensorineural hearing loss that contains a serotonin 3 receptor agonist. Sensorineural hearing loss includes acoustic trauma hearing loss, age-related hearing loss, etc. Also provided is a composition for activating MOC neurons that contains a serotonin 3 receptor agonist. The serotonin 3 receptor agonist activates MOC neurons and thus enables the prevention and treatment of sensorineural hearing loss. Also provided are: a method for screening a compound for preventing or treating sensorineural hearing loss, said method including a step for measuring serotonin 3 receptor agonist activity; and a method for screening a compound activating MOC neurons.
A61K 31/4545 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pipampérone, anabasine
One aspect of the present invention pertains to a manufacturing method for a zeolite catalyst with a silica coating, the method including at least the following: obtaining zinc-doped zeolite by mixing a zinc source and an MFI-type zeolite; preparing a mixture liquid containing a silica source, water, and a structure directing agent containing tetraethylammonium; and adding the mixture liquid to the surface of the zinc-doped zeolite and carrying out hydrothermal synthesis.
B01J 29/40 - Zéolites aluminosilicates cristallines; Leurs composés isomorphes du type pentasil, p.ex. types ZSM-5, ZSM-8 ou ZSM-11
C01B 39/36 - Type pentasil, p.ex types ZSM-5, ZSM-8 ou ZSM-11
C07C 1/20 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir de composés organiques ne renfermant que des atomes d'oxygène en tant qu'hétéro-atomes
The present invention improves the accuracy of prediction of a property value of a material. A method according to an embodiment of the present invention acquires an image of a material, and performs a topological data analysis on the image of the material, to thereby extract a feature of the material and predict a property value of the material from the feature of the material.
G16C 60/00 - Science informatique des matériaux, c. à d. TIC spécialement adaptées à la recherche des propriétés physiques ou chimiques de matériaux ou de phénomènes associés à leur conception, synthèse, traitement, caractérisation ou utilisation
G01N 23/2251 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en mesurant l'émission secondaire de matériaux en utilisant des microsondes électroniques ou ioniques en utilisant des faisceaux d’électrons incidents, p.ex. la microscopie électronique à balayage [SEM]
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
Provided are: a composite material that can be produced by a simple method and has excellent mechanical properties; and a method for producing the composite material. The composite material according to the present invention comprises a cyclic molecule multimer having at least two host groups and a polymeric component, in which each of the host groups is a group having such a structure that one hydrogen atom or one hydroxyl group is removed from cyclodextrin or a cyclodextrin derivative, and the cyclic molecule multimer has such a structure that the at least two host groups are lined to each other through a bivalent or higher group having a linear structure.
Provided is a tetrahydronaphthalene derivative that can be used as an LAT1-selective inhibitor and an LAT1-selective substrate. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), M represents S, O, NH or the like; R1C represents any one structure selected from the group consisting of a 5- to 7-membered aromatic heterocyclic group having a substituent, a C5- to 7-membered aromatic cyclic group having a substituent and a substituted or unsubstituted 8- to 16-membered polycyclic group, or the like; and n represents an integer of 0 to 5. The present invention also relates to a composition for treating cancer, a medicine for BNCT, a diagnostic drug for cancer, an LAT1-selective inhibitor, or a composition for enhancing a BNCT effect, each containing the compound or the pharmaceutically acceptable salt thereof.
C07C 229/50 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino ou carboxyle liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et des groupes carboxyle liés à des atomes de carbone faisant partie du même système cyclique condensé
A61K 31/136 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p.ex. benzène-amine
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/4418 - Pyridines non condensées; Leurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p.ex. cyproheptadine
C07D 213/24 - Composés hétérocycliques contenant des cycles à six chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle et avec au moins trois doubles liaisons entre chaînons cycliques ou entre chaînons comportant trois liaisons doubles ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec des radicaux hydrocarbonés substitués, liés aux atomes de carbone du cycle
The objective of the present invention is to provide an information processing device and program capable of easily establishing connections between a plurality of terminals. An information processing device 1 is connected to a plurality of user terminals (201, 202, 203, 204) used by users, and shares an image signal between the plurality of user terminals (201, 202, 203, 204), the information processing device 1 comprising: an image signal acquiring unit (11) for acquiring image signals output by each of the plurality of user terminals (201, 202, 203, 204); a specifying unit 12 for specifying an image signal having a correspondence relationship with acquired content; a combining unit 13 for establishing a connection between the user terminals (201, 202, 203, 204) outputting the specified image signal, and combining the image signals output from each user terminal (201, 202, 203, 204); and an output unit (14) for outputting the combined image signal to each user terminal (201, 202, 203, 204).
Provided are a processing device and an output device, the processing device being built into the output device which uses a DA converter to output a predetermined voltage value serving as a reference. A processing device 100 is built into an output device 1 which uses a DA converter 16 to output a predetermined voltage value serving as a reference, the processing device 100 comprising: an input voltage acquisition unit 101 which acquires a positive reference voltage value and a negative reference voltage value output, as internal reference voltage values, from an internal power supply 11 in the output device 1; an output voltage acquisition unit which acquires a positive output voltage value and a negative output voltage value output from the DA converter 16; and an adjustment unit 103 which adjusts a set value of the DA converter 16 and adjusts the acquired positive output voltage value and negative output voltage value toward the acquired positive reference voltage value and negative reference voltage value.
The purpose of the present invention is to provide an antibody which inhibits the infection of cells with human norovirus (HuNoV) GII.2. More specifically, the present invention relates to a VHH antibody which binds to human norovirus (HuNoV) GII.2 and inhibits the infection of intestinal cells with HuNoV GII.2. More specifically, the present invention relates to a VHH antibody which inhibits the infection of intestinal cells with HuNoV GII.2, the VHH antibody being characterized in that the amino acid sequences of complementarity-determining regions 1 to 3 (CDR1, CDR2 and CDR3) are the following (A), (B), (C), (D), (E) or (F). (A) CDR1 containing the amino acid sequence represented by SEQ ID NO: 7, CDR2 containing the amino acid sequence represented by SEQ ID NO: 8, and CDR3 containing the amino acid sequence represented by SEQ ID NO: 9. (B) CDR1 containing the amino acid sequence represented by SEQ ID NO: 10, CDR2 containing the amino acid sequence represented by SEQ ID NO: 11, and CDR3 containing the amino acid sequence represented by SEQ ID NO: 12. (C) CDR1 containing the amino acid sequence represented by SEQ ID NO: 13, CDR2 containing the amino acid sequence represented by SEQ ID NO: 14, and CDR3 containing the amino acid sequence represented by SEQ ID NO: 15. (D) CDR1 containing the amino acid sequence represented by SEQ ID NO: 16, CDR2 containing the amino acid sequence represented by SEQ ID NO: 17, and CDR3 containing the amino acid sequence represented by SEQ ID NO: 18. (E) CDR1 containing the amino acid sequence represented by SEQ ID NO: 19, CDR2 containing the amino acid sequence represented by SEQ ID NO: 20, and CDR3 containing the amino acid sequence represented by SEQ ID NO: 21. (F) CDR1 containing the amino acid sequence represented by SEQ ID NO: 22, CDR2 containing the amino acid sequence represented by SEQ ID NO: 23, and CDR3 containing the amino acid sequence represented by SEQ ID NO: 24.
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
88.
ROLLING SITUATION OBSERVATION DEVICE, ROLLING SITUATION OBSERVATION METHOD, ROLLING DEVICE, AND ROLLING METHOD
Provided are: a rolling observation technology that tracks moment-to-moment changes in the rolling situation at one specific point (a material point) on a sheet material that passes through a roll bite from before rolling until after rolling and makes it possible to easily observe the changes in situ; and a rolling technology that is based on observation results from the rolling observation technology. According to the present invention, a rolling situation observation device that observes a rolling situation during the rolling of a workpiece by passage of the workpiece through a roll gap provided between a pair of rolls that rotate in opposite directions comprises a rolling unit that rolls the workpiece by passing the workpiece through the roll gap while moving the axial centers of the pair of rolls at a prescribed speed toward the upstream side of the workpiece but keeping one point on the workpiece at a fixed position and a rolling situation observation unit that observes the rolling situation of the workpiece at a roll bite from the outside in the axial direction of the pair of rolls toward the workpiece.
B21C 51/00 - Dispositifs de mesure, de calibrage, d'indication, de comptage ou de marquage, spécialement conçus pour être utilisés dans la production ou la manipulation des matériaux concernés par les sous-classes
B21B 13/00 - Cages de laminoirs, c. à d. ensembles composés d'un chassis, des cylindres et des accessoires
B21B 35/12 - Mécanismes à roues dentées spécialement adaptés aux laminoirs; Carters ou garnitures de ces mécanismes
89.
AGENT FOR TREATING OR PREVENTING IDIOPATHIC PULMONARY FIBROSIS
NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (Japon)
OSAKA UNIVERSITY (Japon)
RIKEN (Japon)
Inventeur(s)
Kitatani, Natsume, Yayoi
Itoh, Mari
Kuroda, Masataka
Mizuguchi, Kenji
Adachi, Jun
Tomonaga, Takeshi
Kumanogoh, Atsushi
Takeda, Yoshito
Ueda, Naonori
Abrégé
[Problem] To provide an agent for treating or preventing idiopathic pulmonary fibrosis (IPF). [Solution] An agent for treating or preventing IPF, the agent containing an ABL inhibitor, RET inhibitor, SRC family inhibitor, ERK1/2 phosphorylation inhibitor, or FLT3 inhibitor.
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/216 - Esters, p.ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p.ex. bénactizyne, clofibrate
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/4166 - 1,3-Diazoles ayant des groupes oxo liés directement à l'hétérocycle, p.ex. phénytoïne
A61K 31/4436 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle
A61K 31/5025 - Pyridazines; Pyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p.ex. œstrane, œstradiol
90.
TREATMENT-METHOD SELECTION ASSISTANCE DEVICE, TREATMENT-METHOD SELECTION ASSISTANCE METHOD, AND COMPUTER-READABLE MEDIUM
The present invention assists with the selection of a treatment method by displaying the information of a plurality of patients. A treatment-method selection assistance device (10) comprises: a medication history acquisition unit (11) that acquires, as a medication history, the history of administering medication to each patient; a medical condition acquisition unit (12) that acquires the medical condition of each patient; and a display control unit (13) that causes a display device to display a display screen on which the medication histories and medical conditions of the plurality of patients are displayed along a time axis.
G16H 70/40 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des médicaments, p.ex. leurs effets secondaires ou leur usage prévu
91.
ELECTRON BEAM RADIATION DEVICE AND ELECTRON BEAM RADIATION METHOD
This electron beam radiation device comprises: a positioning unit in which an irradiation subject who has a prodrug therein is positioned; and a radiation unit that, once the subject for irradiation is positioned at the positioning unit, irradiates the prodrug inside the irradiation subject with an electron beam having an energy greater than 1 MeV, to transform the prodrug to an active substance.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C07K 14/78 - Peptides du tissu connectif, p.ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid (CIG)
C12N 11/00 - Enzymes fixées sur un support ou immobilisées; Cellules microbiennes fixées sur un support ou immobilisées; Leur préparation
The present invention provides a novel microwave absorber that is not black in color and solid at room temperature. A microwave absorber comprising an imidazolium salt represented by formula (1) [wherein: R1represents a linear alkyl group the carbon atom number of which is not more than the carbon atom number of R2; R2represents an alkyl group having 9 or more carbon atoms; R3and R4 may be either the same or different and represent hydrogen or an alkyl group having 1-6 carbon atoms; and X represents a halogen element] is useful as a novel microwave absorber that is not black in color and solid at room temperature.
C08L 101/00 - Compositions contenant des composés macromoléculaires non spécifiés
B29B 13/08 - Conditionnement ou traitement physique de la matière à façonner par utilisation de l'énergie ondulatoire ou par rayonnement corpusculaire
B29C 45/00 - Moulage par injection, c. à d. en forçant un volume déterminé de matière à mouler par une buse d'injection dans un moule fermé; Appareils à cet effet
The present invention provides a wound treatment device with which there is no increase in infection or delay in healing due to, inter alia, an irrigation liquid leakage or foam adjustment, embedment, or replacement, and that can effectively protect the surroundings of a wound and can be easily handled without requiring skill. The present invention also provides a wound covering used therein. The present invention provides a wound treatment device characterized by comprising a wound covering constituted from a flexible laminate including a porous member and a watertight film member laminated on the porous member, a negative pressure supply pump for supplying negative pressure to the porous member side, an irrigation fluid pump for supplying an irrigation fluid to the porous member side and discharging the irrigation fluid from the porous member side, a canister for intaking the discharged irrigation fluid, and a control unit for controlling the negative pressure supply pump and the irrigation fluid pump, the wound treatment device performing negative pressure wound therapy and irrigation on the wound covered on the porous member side by the wound covering.
Provided are a program and the like capable of accurately evaluating the activity intensity of a physical activity. This computer acquires acceleration data detected by an acceleration sensor worn on a subject in motion. Further, the computer uses the acquired acceleration data to count the frequency of each acceleration and generate the distribution of frequencies of respective accelerations. Then, the computer specifies a gaussian mixture model representing the generated distribution of frequencies of the respective accelerations.
A transcranial electrical stimulation device (1) is provided with: positive and negative electrodes (31) that are installed on respective surfaces of a head corresponding to holes opened in the cranial, such as proximate or opposite surfaces of the head, to form a current path through which a stimulation current flows in the brain ventricle; and a magnet unit (40) that has a small magnetic pole surface (431) that abuts on the surface of the head to provide a local magnetic field for locally changing the current path through an interaction with the stimulation current. In this way, the localized magnetic field is interacted with the stimulation current to thereby locally change the current path of the stimulation current in the brain by means of Lorentz force.
[Problem] To provide a power generation method and a power generation system that utilize water radiolysis. [Solution] A power generation method for generating power through water radiolysis, the power generation method comprising: a step for preparing a power generation tank that is capable of containing water and has a pair of electrodes disposed therein, and dispersing metal oxide particles having oxygen non-stoichiometry and conductivity in the water; a step for irradiating the water containing the metal oxide particles dispersed therein with radiation from a radiation source; a step for locally depositing the metal oxide particles in the vicinity of one of the electrodes after the radiation irradiation; and a step for extracting electricity from the electrodes.
The present invention provides a vibration device which stabilizes vibration of a probe over a long period of time. The vibration device (1) is for causing a cantilever-supported probe to vibrate, said vibration device comprising a probe (2), two securing members (3, 4) supporting the probe (2) sandwiched therebetween, and vibration-generating unit (5) for imparting vibrations to at least one of the two securing members (3, 4), wherein a recess (10) in which the probe (2) is placed is formed on at least one of the two securing members (3, 4) at the position corresponding to the probe (2) when the probe (2) is sandwiched by the two securing members (3, 4).
G01N 27/62 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant les décharges électriques, p.ex. l'émission cathodique
H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p.ex. fermetures étanches au vide; Dispositions pour le réglage externe des composants électronoptiques ou ionoptiques
H01J 49/16 - Sources d'ions; Canons à ions utilisant une ionisation de surface, p.ex. émission thermo-ionique ou photo-électrique
H01J 49/26 - Spectromètres de masse ou tubes séparateurs de masse
100.
METHOD FOR PRODUCING RADIOLABELED ARYL COMPOUND BY ELECTROLYTIC OXIDATION REACTION
[Problem] The present invention addresses the problem of providing a novel method for, under simpler and stabler conditions, labeling a radionuclide such as 211At at a high radiochemical yield. [Solution] Provided is a method for producing an aryl compound labelled with a radionuclide, the method comprising: a step for applying a voltage to a solution A comprising a radionuclide, and electrolytically oxidizing the radionuclide; and a step for mixing the solution A and a solution B comprising a compound S having a halogenated aryl group to replace a halogen atom on the aryl group of the compound S with the radionuclide.